What do systematic reviews say?

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  9 studies · 1942 participants
  Low

Intervention not reported

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  no estimate extracted
  16 studies · 3934 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in total number of adverse events (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.04 [0.98, 1.1]
  15 studies · 3284 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in number of participants with exacerbations requiring systemic steroids (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.69 [0.85, 3.32]
  3 studies · 581 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in number of participants with exacerbations requiring hospitalisation (moderate certainty).

• Addition of long‐acting beta₂‐agonists to inhaled corticosteroids for chronic asthma in children 2015 · Cochrane Headline outcomes only
  RR 1.9 [0.65, 5.54]
  4 studies · 1008 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA showed no clear difference in exacerbation: systemic corticosteroids 17 weeks compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 1.74 [0.83, 3.65]
  4 studies · 1257 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 645 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA showed no clear difference in serious adverse events 17 weeks compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 0.82 [0.28, 2.42]
  5 studies · 1342 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 359 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1342 participants
  Low

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA showed no clear difference in adverse events (all) compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 0.83 [0.66, 1.05]
  5 studies · 1339 participants
  Moderate

Stopping LABA vs continuing use of LABA+ICS

Stopping LABA probably leads to higher withdrawal (all) compared with continuing use of LABA+ICS (moderate certainty).

• Stopping long‐acting beta₂‐agonists (LABA) for adults with asthma well controlled by LABA and inhaled corticosteroids 2015 · Cochrane Headline outcomes only
  OR 1.95 [1.47, 2.58]
  5 studies · 1352 participants
  Moderate

LABA/ICS vs LTRA + ICS

LABA + ICS leads to lower participants with one or more exacerbations requiring systemic… compared with LTRA + ICS (high certainty).

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  RR 0.87 [0.76, 0.99]
  8 studies · 6257 participants
  High

LABA/ICS vs LTRA + ICS

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 6161 participants
  Moderate

LABA/ICS vs LTRA + ICS

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  10 studies · 4999 participants
  High

LABA/ICS vs LTRA + ICS

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 2612 participants
  Moderate

LABA/ICS vs LTRA + ICS

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  no estimate extracted
  7 studies · 4055 participants
  High

LABA/ICS vs LTRA + ICS

LABA + ICS probably leads to lower withdrawals for any reason compared with LTRA + ICS (moderate certainty).

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  RR 0.84 [0.74, 0.96]
  13 studies · 6960 participants
  Moderate

LABA/ICS vs LTRA + ICS

LABA + ICS showed no clear difference in serious adverse events compared with LTRA + ICS (moderate certainty).

• Addition to inhaled corticosteroids of long‐acting beta₂‐agonists versus anti‐leukotrienes for chronic asthma 2014 · Cochrane Headline outcomes only
  RR 1.33 [0.99, 1.79]
  9 studies · 6288 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in SGRQ Scores range from 0 to 100, with higher scores indicating more… (low certainty).

• Combination inhaled corticosteroids and long‐acting beta₂‐agonists for children and adults with bronchiectasis 2014 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 40 participants
  Low